
Opinion|Videos|December 15, 2023
Novel Therapy Impact on Patient Quality of Life
Novel therapies in MDS treatment are evaluated by a panel of experts led by Dr Haumschild.
Advertisement
Episodes in this series

Advertisement
Related to this article

At a roundtable in Cleveland, kidney experts said IgA nephropathy and FSGS often go unrecognized, calling for EHR flags and better referral channels.

Labial gland biopsy may support diagnosis of neurologic Sjögren disease, especially when antibody tests are negative or inconclusive.

This analysis in RR MCL shows CAR T-cell therapy (brexucabtagene) yields higher complete responses vs bispecific antibodies; durability remains unclear.

Meta-analysis finds oral JAK inhibitors like baricitinib and ritlecitinib drive strong alopecia areata hair regrowth, improving SALT scores with manageable safety.

Follitropin delta yields cumulative ongoing pregnancy in 64.0% of patients under 35 and 43.9% of those 35 to 42 in 2 placebo-controlled IVF trials.

The Ambulatory Specialty Model aims to reduce chronic disease costs by mandating specialist participation and tying payments to quality and cost, while posing nationwide risk challenges.
Advertisement
Advertisement
Trending on AJMC
1
Medicare Drug Price Negotiations Yield Uneven Out-of-Pocket Savings
2
Rusfertide Keeps Working Where Hydroxyurea Fades: Andrew Kuykendall, MD
3
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
4
Lymphoma Outcomes Hinge on Oncology, Not Viral Load In People With HIV
5


